Effects of clarithromycin, azithromycin and rifampicin on terbutaline‐induced sweating in foals

Authors:

Abstract
Summary: Background: Erythromycin ( ERY ) induces anhidrosis in foals. Azithromycin ( AZI ) and clarithromycin ( CLA ), often combined with rifampicin ( RIF ), are commonly used to treat Rhodococcus equi infections, but effects on sweating have not been investigated. Objective: To determine the effects of AZI , CLA and RIF on sweat responses in normal foals. Study design: Each experiment was a blinded, duplicated, six foal × three period counterbalanced within subjects design (12 foals/experiment). Methods: Antimicrobials were given orally for 5 days. In Experiment 1, ERY , AZI and CLA were given. In Experiment 2, ERY , RIF and ERY / RIF combination were used. Quantitative intradermal terbutaline sweat tests were performed daily for 3 days before and 1, 2, 5, 9, 24, and 39 days after treatment. Data were analysed by repeated measures analysis of variance procedures. Significance was P≤0.05. Results: In Experiment 1, all macrolides suppressed sweating although CLA and AZI were less potent than ERY . In Experiment 2, significant sweat suppression occurred in foals given ERY with or without RIF , but there was no effect of RIF alone. Rifampicin reduced sweat suppression by ERY on Day 1 of treatment but not thereafter. Main limitations: Because ERY blood concentrations were not measured, effects of RIF on ERY ‐induced anhidrosis could not definitively be ascribed to altered ERY bioavailability. Conclusions: All macrolides commonly used to treat R. equi pneumonia, i.e. ERY , AZI and CLA , induce anhidrosis in foals. The potent anti‐sudorific effect of ERY is delayed, but not substantially affected by concurrent RIF administration.
Funding Information
  • Grayson-Jockey Club Research Foundation

This publication has 18 references indexed in Scilit: